956699-06-2

Basic information

• Product Name: 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine
• Synonyms: 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine
• CAS NO: 956699-06-2
• Molecular Formula: C11H17N3O
• Molecular Weight: 207.28
• Mol File: 956699-06-2.mol

Chemical Properties

• Boiling Point: 406.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.101±0.06 g/cm3(Predicted)
• PKA: 6.52±0.24(Predicted)
• CAS DataBase Reference: 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine(956699-06-2)
• EPA Substance Registry System: 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine(956699-06-2)

Safety Data

• Hazardous Substances Data: 956699-06-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine is employed as a key intermediate in the synthesis of bioactive compounds and potential drug candidates. Its unique structure and the presence of morpholine and pyridine moieties make it a versatile and important chemical in medicinal chemistry, facilitating the development of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine is used as a building block for the creation of novel compounds with potential therapeutic applications. Its solubility and stability, attributed to the morpholine and pyridine components, enhance its utility in the design and synthesis of pharmaceutically relevant molecules.

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 276252-73-4 (+/-)-trans-2,6-dimethylmorpholine 
• 260447-04-9 (25,6R)-2,6-dimethyl-4-(5-nitropyridin-2-yl)morpholine 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 260447-04-9 (2S,6R)-2,6-dimethyl-4-(5-nitropyridin-2-yl)morpholine 
• 141-91-3 cis-2,6-dimethylmorpholine 
• 260447-04-9 cis-2,6-dimethyl-4-(5-nitropyridin-2-yl)morpholine 

Downstream Products

• 1221721-86-3 3-bromo-N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methylbenzamide 
• 956697-53-3 Erismodegib 
• 1218778-77-8 N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4’-(trifluoromethoxy)-[1,1‘-biphenyl]-3-carboxamide diphosphate 

Relevant articles and documents

High Turnover Pd/C Catalyst for Nitro Group Reductions in Water. One-Pot Sequences and Syntheses of Pharmaceutical Intermediates

Commercially available Pd/C can be used as a catalyst for nitro group reductions with only 0.4 mol % Pd loading. The reaction can be performed using either silane as a transfer hydrogenating agent or simply a hydrogen balloon (μ1 atm pressure). With this technology, a series of nitro compounds was reduced to the desired amines in high chemical yields. Both the catalyst and surfactant were recycled several times without loss of reactivity.

SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Preparation methods of Sonidegib intermediate and Sonidegib

The invention provides preparation methods of a Sonidegib intermediate and Sonidegib. According to the preparation methods, 2-amino-5-nitropyridine (II) and R-propylene oxide (or S-propylene oxide) are subjected to an epoxy ring-opening substitution react

Smo inhibitor as well as synthesis method and application thereof

The invention discloses an Smo inhibitor as well as a synthesis method and application thereof. A structural formula of the Smo inhibitor is shown by a formula (I) as shown in the specification. The invention also discloses the synthesis method and the application of the Smo inhibitor. According to the invention, nilotinib is optimized into the dual-targeted inhibitor being active against Smo andBcr-Abl, and the inhibitor can overcome the tolerance problem caused by single-targeted drugs, has the advantages of improving anti-tumor efficacy and reducing toxic or side effects, and provides a reference for future research on dual-targeted anti-hematologic malignant drugs.

As Hedgehog signal transduction pyrimidine amines and pyridine amine inhibitors

The invention relates to pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors. The inhibitors are compounds with the structure represented by formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to a medicinal use of the above compounds as hedgehog signal conduction inhibitors.

An environmentally responsible 3-pot, 5-step synthesis of the antitumor agent sonidegib using ppm levels of Pd catalysis in water

The current industrial approach to sonidegib utilizes wasteful organic solvents and relies on high loadings of endangered Pd. This anticancer drug can now be synthesized in 5 steps using only 3 pots, along with ppm levels of a Pd catalyst, all done in water at ambient temperatures.

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors

The Hedgehog (Hh) signaling pathway is associated with diverse aspects of cellular events, such as cell migration, proliferation, and differentiation throughout embryonic development and tissue patterning. An abnormal Hh signaling pathway is linked to numerous human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB), lung cancer, prostate cancer, and ovarian cancer, and it is therefore a promising target in cancer therapy. Using a structure-hopping approach, we designed new Hh signaling pathway inhibitors with isoindolinone or quinazolinone moieties, which were synthesized and biologically evaluated using an 8xGli-luciferase (Gli-Luc) reporter assay in NIH3T3 cells. Compounds 9–11 and 14 with isoindolinone scaffolds demonstrated moderate Hh inhibitory activity; whereas quinazolinone derivatives 24, 29, 32, 34, and 35 exhibited good potency with submicromolar IC50values and the analog 28 showed nanomolar IC50value. Although sonidegib shows a decrease in inhibitory effect on vismodegib resistance-conferring Smo mutants, the structurally modified new compounds not only possess the pharmacophoric properties of Hh pathway inhibition but also preserve the suppressive potency in drug-resistant Smo mutants. Mechanistically, quinazolinone derivatives 28 and 34 suppress Hh signaling by blocking Smo and Gli translocation into the cilia, similar to vismodegib and sonidegib. Additionally, the human microsomal stability of the representative analogs 28 and 34 were determined to be comparable to that of the reference compound sonidegib. Thus, these new scaffolds can serve as a platform for the development of novel cancer therapeutics targeting the Hh pathway.

Hedgehog signal pathway inhibitor

The invention provides a Hedgehog signal pathway inhibitor as well as stereoisomers, tautomers, hydrates, solvates or pharmaceutically acceptable salts thereof, and the structural formula of the inhibitor is as shown in a formula (I). The invention further provides a preparation method and application of a compound. The compound provided by the invention is novel in structure; a signal transduction pathway adjusted by Hedgehog protein, Ptch, Gli and/or Smo can be adjusted through the compound of the formula I.

PROCESS FOR THE PREPARATION OF N-[6-(CIS-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDINE-3-YL]-2- METHYL-4'-(TRIFIUOROMETHOXY) [1,1' -BIPHENYI]-3-CARBOXAMIDE AND ITS POLYMORPHS THEREOF

The present invention relates to process for the preparation of N-[6-(cis-2,6-dimethyl morpholin-4-yl)pyridine-3-yl]-2-methyl-4' -(trifluoromethoxy) [1,1'-biphenyl]-3-carboxamide compound of formula-1, it's salts and their polymorphs thereof.